Brief Report-Reference-Cited by-同舟云学术

Brief Report

Published:2015-07-01 Issue:3 Volume:69 Page:338-340
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Gallant Joel E.,Koenig Ellen,Andrade-Villanueva Jaime F.,Chetchotisakd Ploenchan,DeJesus Edwin,Antunes Francisco,Arastéh Keikawus,Rizzardini Giuliano,Fehr Jan,Liu Hui C.,Abram Michael E.,Cao Huyen,Szwarcberg Javier

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference15 articles.

1. . Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer.;Xu;ACS Med Chem Lett,2010

2. . Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.;Mathias;Clin Pharmacol Ther,2010

3. . A randomized, double-blind comparison of single-tablet regimen elvitegravircobicistatemtricitabinetenofovir DF vs ritonavir-boosted atazanavir plus emtricitabinetenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.;Clumeck;J Acquir Immune Defic Syndr,2014

4. . Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabinetenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.;Gallant;J Infect Dis,2013

5. . Randomized, phase 2 evaluation of two single-tablet regimens elvitegravircobicistatemtricitabinetenofovir disoproxil fumarate versus efavirenzemtricitabinetenofovir disoproxil fumarate for the initial treatment of HIV infection.;Cohen;AIDS,2011

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection;Retrovirology;2022-10-22

2. Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat;Biomedicines;2021-03-18

3. The crosstalk between antiretrovirals pharmacology and HIV drug resistance;Expert Review of Clinical Pharmacology;2020-06-30

4. Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens: A meta-analysis of randomized controlled trials;International Journal of Infectious Diseases;2019-10

5. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy;HIV Clinical Trials;2018-09-03